EU close to fast-tracking COVID-19 treatment drug

Video credit: Reuters Studio
Published 3 weeks ago - Duration: 01:40s

EU close to fast-tracking COVID-19 treatment drug

The head of the European Union's medicines agency, Guido Rasi, has said an initial authorization for U.S. pharmaceutical company Gilead's remdesivir as a COVID-19 treatment could be granted in coming days.

Joe Davies reports.


EU close to fast-tracking COVID-19 treatment drug

The European Union may give an initial green light in the coming days for the sale of the drug remdesivir as a COVID-19 treatment -- fast-tracking the drug to market -- and the latest in a tight global competition for resources to fight the pandemic.

It also comes after the United States angered the EU with its aggressive tactics in obtaining such resources.

The U.S. has yet to issue a similar approval for the drug.

Guido Rasi is head of the EU Medicines Agency: "Now, there is an ongoing rolling review in the EMA to support the CHMP's (human medicines committee) decision, and it might be that a conditional market authorization can be issued in the coming days, subject to the data that we've submitted and how the experts will deem those data robust enough to issue what I expect could be the conditional approval.

I don't see another kind of approval at this stage." The European Medicines Agency - or EMA - has already recommended the compassionate use of remdesivir, which allows a drug to be administered to patients even before its sale has been authorised.

Demand for remdesivir has been growing as there are currently no approved treatments or vaccines for COVID-19.

It's made by U.S. pharmaceutical company Gilead.

They're now negotiating long-term licenses with drugmakers in India and Pakistan to produce remdesivir for developing countries.

But it's unclear how soon sufficient amounts of the drug could be available to meet the world's need for a treatment.

You are here

Related news from verified sources

No major side-effects of Hydroxychloroquine (HCQ) have been found in studies in India and its use should be continued in preventive treatment for Covid-19, the...
2 weeks ago • IndiaTimes

No major side-effects of Hydroxychloroquine (HCQ) have been found in studies in India and its use should be continued in preventive treatment for Covid-19, the...
2 weeks ago • IndiaTimes

Fujifilm Holdings Corp will continue research on Avigan into June, Japan's government said on Tuesday, effectively dashing hopes by Prime Minister Shinzo Abe...
2 weeks ago • Reuters India

Related videos from verified sources

โ€˜Not ayurvedicโ€™: CSIR on plant-based drug ACQH to be tested for Covid treatment 01:59
Video credit: HT Digital Content - Published 9 hours ago 

WHO set to resume hydroxychloroquine trial to battle covid-19 02:33
Video credit: HT Digital Content - Published 2 days ago 

Hydroxychloroquine no better than placebo, study finds 01:56
Video credit: Reuters - Politics - Published 3 days ago